Idiopathic Pulmonary Fibrosis and the Effects of Treatment

Share this article with:

About 50,000 people in the United States are diagnosed with IPF each year. After diagnosis, the estimated survival is only 3 years. Patients with IPF deteriorate to the extent that most die of respiratory failure; essentially their lungs can’t get enough oxygen into their blood.

The animation, developed in partnership with Wedgewood Communications, shows the mechanism of disease for IPF and the mechanism of action for the recently-approved agent OFEV (nintedanib) from Boehringer Ingelheim.

The 6.5-minute animation shows in great detail how the lungs work to get oxygen into the blood, how the lung tissue is repaired when damage occurs, and how this repair process goes awry in IPF.

Share It:
Contact XVIVO


Idiopathic Pulmonary Fibrosis and the Effects of Treatment

XVIVO has produced several high quality animation videos for us and we will keep going back to them with future projects. This company provides exceptional customer service and has been a pleasure to work with.

Sr. Manager, New Products Marketing, Kinetic Concepts, Inc. (KCI)